Literature DB >> 8222155

Intraoperative device closure of ventricular septal defects.

S B Fishberger1, N D Bridges, J F Keane, F L Hanley, R A Jonas, J E Mayer, A R Castaneda, J E Lock.   

Abstract

BACKGROUND: Surgical repair of muscular ventricular septal defects (VSDs) has been associated with significant morbidity and mortality when the defects are multiple, associated with complex cardiac lesions, or requiring left ventriculotomy. Transcatheter VSD closure may be difficult in patients weighing less than 7 kg or those with limited vascular access. We attempted intraoperative device closure of muscular VSDs during surgical repair of associated lesions. METHODS AND
RESULTS: We considered intraoperative umbrella closure in 10 patients, 8 with additional complex heart lesions. "Swiss cheese" defects were present in 4. Median patient age was 4.7 months. Device closure was not attempted in 1 patient due to an inadequate septal rim. Nine umbrellas, 12 to 40 mm in diameter, were positioned to straddle the septum in all 9 patients. There were 3 early deaths, 2 in patients who were moribund preoperatively. The third was due to severe ventricular dysfunction. Among the 6 survivors, 3 had a Qp:Qs < or = 2 and right ventricular or pulmonary artery pressure less than half systemic. These patients had no further intervention. The other 3 had a Qp:Qs > 2. One died unexpectedly 5 weeks after cardiac surgery. The other 2 had subsequent closure of residual VSDs. All 5 survivors are well at follow-up of 8 to 25 months.
CONCLUSIONS: Intraoperative umbrella VSD closure appears less successful than VSD closure in the catheterization laboratory. In selected patients, particularly very small infants, intraoperative device placement may be advantageous. Completeness of closure is difficult to assess intraoperatively.

Entities:  

Mesh:

Year:  1993        PMID: 8222155

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Ventricular Septal Defect.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-12

Review 2.  Surgical management of muscular trabecular ventricular septal defects.

Authors:  Toshihide Asou
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-11-15

3.  Hybrid pediatric cardiac surgery.

Authors:  E A Bacha; Z M Hijazi; Q-L Cao; R Abdulla; J P Starr; J Quinones; P Koenig; B Agarwala
Journal:  Pediatr Cardiol       Date:  2005 Jul-Aug       Impact factor: 1.655

4.  Multicenter experience with perventricular device closure of muscular ventricular septal defects.

Authors:  E A Bacha; Q L Cao; M E Galantowicz; J P Cheatham; C E Fleishman; S W Weinstein; P A Becker; S L Hill; P Koenig; E Alboliras; R Abdulla; J P Starr; Z M Hijazi
Journal:  Pediatr Cardiol       Date:  2005 Mar-Apr       Impact factor: 1.655

5.  Perventricular closure of muscular ventricular septal defects: How do I do it?

Authors:  Karim A Diab; Qi-Ling Cao; Ziyad M Hijazi
Journal:  Ann Pediatr Cardiol       Date:  2008-01

Review 6.  Techniques and results in the management of multiple muscular trabecular ventricular septal defects.

Authors:  Tetsuya Kitagawa; Takashi Kitaichi; Mikio Sugano; Hirotsugu Kurobe
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-06-05

7.  Multiple ventricular septal defects: a new strategy.

Authors:  Antonio F Corno; Pramod R Kandakure; Ramana Rao V Dhannapuneni; Gordon Gladman; Prem Venugopal; Nelson Alphonso
Journal:  Front Pediatr       Date:  2013-07-31       Impact factor: 3.418

8.  The hybrid perventricular closure of apical muscular ventricular septal defect with Amplatzer duct occluder.

Authors:  Soo Jin Kim; June Huh; Jin Young Song; Ji-Hyuk Yang; Tae-Gook Jun; I-Seok Kang
Journal:  Korean J Pediatr       Date:  2013-04-22

9.  Hybrid muscular ventricular septal defect closure in a 4.5 kg infant followed by sildenafil treatment and transcatheter atrial septal defect occlusion.

Authors:  Michal Galeczka; Roland Fiszer; Szymon Pawlak; Joanna Sliwka; Linda Litwin; Malgorzata Szkutnik
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-03-22       Impact factor: 1.426

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.